首页> Gut: Journal of the British Society of Gastroenterology> Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic

Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic

导出原文传递

翻译打印收藏纠错

第一作者： Nicholas A Kennedy

作者： Nicholas A Kennedy ^[1] ; Malik Janjua ^[2] ; Neil Chanchlani ^[3] ; Simeng Lin ^[4] ; Claire Bewshea ^[5] ; Rachel Nice ^[6] ; Timothy J McDonald ^[7] ; Cressida Auckland ^[8] ; Lorna W Harries ^[9] ; Merlin Davies ^[10] ; Stephen Michell ^[11] ; Klaartje B Kok ; Christopher A Lamb ; Philip J Smith ; Ailsa L Hart ; Richard CG Pollok ; Charlie W Lees ; Rosemary J Boyton ; Daniel M Altmann ; Shaji Sebastian ; Nicholas Powell ; James R Goodhand ; Tariq Ahmad

作者单位： Department of Gastroenterology ^[1] Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group ^[2] Royal Devon and Exeter NHS Foundation Trust ^[3] University of Exeter ^[4] Centre for Immunobiology, Blizard Institute, Barts and the London School of Medicine ^[5] Department of Gastroenterology;Newcastle upon Tyne Hospitals NHS Foundation Trust ^[6] Department of Gastroenterology, Royal Liverpool Hospital ^[7] Department of Gastroenterology;St George's University Hospitals NHS Foundation Trust ^[8] Department of Infectious Disease ^[9] Imperial College London ^[10] IBD Unit, Department of Gastroenterology ^[11]

关键词 infliximab COVID-19 inflammatory bowel disease vedolizumab immunosuppression vaccination biological

发布时间 2023-06-07

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交